PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSevelamer
Renagel(sevelamer)
Renagel, Renvela, Tasermity (sevelamer) is a small molecule pharmaceutical. Sevelamer was first approved as Renagel on 1998-10-30. It is used to treat hyperphosphatemia in the USA. It has been approved in Europe to treat hyperphosphatemia and renal dialysis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
therapeuticsD013812
Trade Name
FDA
EMA
Renagel, Renvela, Sevelamer (discontinued: Renagel, Sevelamer)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sevelamer hydrochloride
Tradename
Company
Number
Date
Products
RENAGELSanofiN-021179 RX2000-07-12
2 products, RLD, RS
Show 1 discontinued
Sevelamer carbonate
Tradename
Company
Number
Date
Products
RENVELASanofiN-022318 RX2009-02-18
2 products, RLD, RS
RENVELASanofiN-022127 RX2007-10-19
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
renagelNew Drug Application2018-02-14
renvelaNew Drug Application2023-09-25
sevelamer carbonateNDA authorized generic2025-02-07
sevelamer carbonate for oral suspensionANDA2023-03-24
sevelamer hydrochlorideANDA2024-11-06
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hyperphosphatemia—D054559—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Sevelamer Carbonate, Renvela, Genzyme
90955092030-12-06DP
Sevelamer Carbonate, Renvela, Sanofi
79854182025-10-27DP
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemia
— V03AE02: Sevelamer
HCPCS
No data
Clinical
No data
Drug
General
Drug common nameSevelamer
INNsevelamer
Description
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
Classification
Small molecule
Drug classpolymers
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=CCN.ClCC1CO1
Identifiers
PDB—
CAS-ID1392212-84-8
RxCUI—
ChEMBL IDCHEMBL1201798
ChEBI ID—
PubChem CID3085017
DrugBankDB00658
UNII ID941N5DUU5C (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Sevelamer
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use